<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"
	"http://www.w3.org/TR/1998/REC-html40-19980424/loose.dtd">
<html>
<head><meta http-equiv="content-type" content="text/html; charset=UTF-8">
<style type="text/css">
 table.main {}
 tr.row {}
 td.cell {}
 div.block {}
 div.paragraph {}
 .font0 { font:5pt Arial, sans-serif; }
 .font1 { font:6pt Arial, sans-serif; }
 .font2 { font:7pt Arial, sans-serif; }
 .font3 { font:9pt Arial, sans-serif; }
 .font4 { font:10pt Arial, sans-serif; }
 .font5 { font:14pt Arial, sans-serif; }
 .font6 { font:18pt Arial, sans-serif; }
 .font7 { font:20pt Arial, sans-serif; }

</style>
</head>
<body>
<p><span class="font5">Deutsche Bank</span></p>
<p><span class="font5">Markets Research</span></p>
<div>
<p><span class="font4">Rating</span></p><a name="caption1"></a>
<h2><a name="bookmark0"></a><span class="font7"><a name="bookmark1"></a>Buy</span></h2>
<p><span class="font3">Asia</span></p>
<p><span class="font4">China</span></p>
<p><span class="font3">Health Care</span></p>
<p><span class="font4">Health Care</span></p>
</div><br clear="all">
<div>
<p><span class="font4">Company</span></p>
<h2><a name="bookmark2"></a><span class="font7"><a name="bookmark3"></a>Phoenix Healthcare</span><br><br><span class="font7"><a name="bookmark4"></a>Group</span></h2>
<p><span class="font2">Reuters &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Bloomberg &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exchange Ticker</span></p>
<p><span class="font2">1515.HK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1515 HK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;HKG 1515</span></p>
</div><br clear="all">
<div>
<h3><a name="bookmark5"></a><span class="font6"><a name="bookmark6"></a>Continue to expect growth acceleration in 2016</span></h3>
<p><span class="font3">1H15 below expectation, but we still expect growth acceleration in 2016 Phoenix reported revenue/EPS of RMB602m/0.12, below Deutsche Bank ests. of RMB688m/0.15. These represent 19%/26% YoY growth. While we do not have details on the additional RMB10m in other income, we roughly estimate core profit growth might be around high-teen. Core EBITDA margin contracted by 150bps due to salary inflation and stock incentives. Management indicated that growth acceleration is likely for Jian Gong and Jing Mei Hospital, while growth momentum of Yan Hua Hospital shall continue. Additionally, margin expansion should occur for Jing Mei and Yan Hua hospitals in 2016. Buy.</span></p>
<p><span class="font3">Strong growth outlook for 2H15 and 2016</span></p>
<p><span class="font3">We previously expected growth deceleration for 2015 due to the absence of acquisitions in 2014. However, the slightly weaker-than-expected revenue growth in all Tier 2 hospitals was a minor surprise. We expect consolidation of two or three hospitals from Baoding and General Coal hospital in 4Q15, which will contribute RMB33m and RMB15m management fees in 2016, respectively. For the largest three hospitals, we expect Jing Mei to see growth acceleration and Yan Hua to maintain growth momentum. Margins for these two hospitals are likely to improve due to mix changes and cost control. As salary inflation affected margin structure in 2H14 and 1H15, we expect GM/OPM stabilization in 2H15. We expect modest growth acceleration for Jian Gong due to a low base, increase of maternity activities, and service mix changes.</span></p>
</div><br clear="all">
<div>
<p><span class="font3">Date</span></p>
<p><span class="font4">11 August 2015</span></p>
<h4><a name="bookmark7"></a><span class="font5"><a name="bookmark8"></a>Results</span></h4>
</div><br clear="all">
<div>
</div><br clear="all">
<div>
<table border="1">
<tr><td style="vertical-align:top;">
<p><span class="font2">Price at 10 Aug 2015 (HKD)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">12.78</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">Price target - 12mth (HKD)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">20.00</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">52-week range (HKD)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">16.50 -10.72</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">HANG SENG INDEX</span></p></td><td style="vertical-align:top;">
<p><span class="font2">24,552</span></p></td></tr>
</table>
<p><span class="font2">Jack Hu. Ph.D</span></p>
<p><span class="font2">Research Analyst (+852 ) 220 3 6 208</span></p>
<p><a href="mailto:jack.hu@db.com"><span class="font2">jack.hu@db.com</span></a></p>
<p><span class="font2">Line Yiu</span></p>
<p><span class="font2">Research Associate (+852) 2203 6248 </span><a href="mailto:linc.yiu@db.com"><span class="font2">linc.yiu@db.com</span></a></p>
</div><br clear="all">
<div>
</div><br clear="all">
<div>
</div><br clear="all">
<p><span class="font3">Focusing on IOT, but exploring other novel business models</span></p>
<p><span class="font3">On business strategies, management highlighted three key themes. Firstly, the company will remain focused on IOT model within the Beijing/Tianjing/Hebei area. Secondly, the company will focus on a regional integrated delivery system (RIDS) to address the trend of separating outpatients from Tier 1 hospitals. Thirdly, management reiterated its interests in senior care to capture the opportunities arising from an aging population.</span></p>
<p><span class="font3">Maintaining price target of HKD20; risks</span></p>
<p><span class="font3">We maintain our price target of HK20, based on 22x 2016E EV/EBITDA of RMB564m. We believe 22x is justified, as its Asian peers are trading at 17x with 10% growth (vs. 50% we model for PHG). Risks include policy changes, lower ASP growth, reimbursement budgeting, and time line of consolidation.</span></p>
<table border="1">
<tr><td colspan="3" style="vertical-align:top;">
<p><span class="font2">| Forecasts And Ratios</span></p></td><td rowspan="2" style="vertical-align:bottom;">
<p><span class="font2">2015E</span></p></td><td rowspan="2" style="vertical-align:bottom;">
<p><span class="font2">2016E</span></p></td><td rowspan="2" style="vertical-align:bottom;">
<p><span class="font2">2017E</span></p></td></tr>
<tr><td style="vertical-align:bottom;">
<p><span class="font2">Year End Dec31</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2013A</span></p></td><td style="vertical-align:bottom;">
<p><span class="font2">2014A</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">Sales (CNYm)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">887.4</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1,206.2</span></p></td><td style="vertical-align:top;">
<p><span class="font2">1,430.2</span></p></td><td style="vertical-align:top;">
<p><span class="font2">2,165.7</span></p></td><td style="vertical-align:top;">
<p><span class="font2">2,746.5</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">EBITDA (CNYm)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">241.6</span></p></td><td style="vertical-align:top;">
<p><span class="font2">300.2</span></p></td><td style="vertical-align:top;">
<p><span class="font2">377.1</span></p></td><td style="vertical-align:top;">
<p><span class="font2">564.0</span></p></td><td style="vertical-align:top;">
<p><span class="font2">718.0</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">DB EPS FD(CNY)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.20</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.25</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.31</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.44</span></p></td><td style="vertical-align:top;">
<p><span class="font2">0.57</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">DB EPS growth (%)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">10.8</span></p></td><td style="vertical-align:top;">
<p><span class="font2">27.0</span></p></td><td style="vertical-align:top;">
<p><span class="font2">20.8</span></p></td><td style="vertical-align:top;">
<p><span class="font2">43.7</span></p></td><td style="vertical-align:top;">
<p><span class="font2">30.3</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">PER (x)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">47.0</span></p></td><td style="vertical-align:top;">
<p><span class="font2">39.3</span></p></td><td style="vertical-align:top;">
<p><span class="font2">33.5</span></p></td><td style="vertical-align:top;">
<p><span class="font2">23.3</span></p></td><td style="vertical-align:top;">
<p><span class="font2">17.9</span></p></td></tr>
<tr><td style="vertical-align:top;">
<p><span class="font2">EV/EBITDA (x)</span></p></td><td style="vertical-align:top;">
<p><span class="font2">21.1</span></p></td><td style="vertical-align:top;">
<p><span class="font2">25.7</span></p></td><td style="vertical-align:top;">
<p><span class="font2">22.8</span></p></td><td style="vertical-align:top;">
<p><span class="font2">14.9</span></p></td><td style="vertical-align:top;">
<p><span class="font2">11.4</span></p></td></tr>
<tr><td colspan="6" style="vertical-align:bottom;">
<p><span class="font0" style="font-weight:bold;font-style:italic;">Source: Deutsche Bank estimates, company c/ata</span></p></td></tr>
</table>
<p><span class="font0" style="font-weight:bold;"><sup>2</sup> Multiples and yields calculations tee average historical prices for past years andspot prices for current and future years, except P/B which ises the year end close</span></p>
<p><span class="font3">Deutsche Bank AG/Hong Kong</span></p>
<p><span class="font3">Deutsche Bank does and seeks to do business with companies covered in its research reports. Thus, investors should</span></p>
<p><span class="font3">be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should</span></p>
<p><span class="font3">consider this report as only a single factor in making their investment decision. DISCLOSURES AND ANALYST</span></p>
<p><span class="font3">CERTIFICATIONS ARE LOCATED IN APPENDIX 1. MCI (P) 124/04/2015.</span></p>
</body>
</html>